COVID-19 - Therapeutic Pipeline for Vaccines - 2020
‘COVID-19 (Novel Coronavirus 19) - Therapeutic Pipeline for Vaccines - 2020’ report delivers an in-depth understanding of the Covid-19 therapeutic vaccines that are currently under development by various companies across the globe.
New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "COVID-19 - Therapeutic Pipeline for Vaccines - 2020" - https://www.reportlinker.com/p05932729/?utm_source=GNW
It also highlights key emerging market trends across the globe with a major focus on key geographies like the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geography Covered
• Global coverage
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Understanding
COVID-19 (Novel Coronavirus 19) and Therapeutic Vaccines: Overview
The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared the ongoing outbreak as a global public health emergency. Currently, the research on novel coronavirus is still in the primary stage. In late December 2019, a case of unidentified pneumonia was reported in Wuhan, Hubei Province, People’s Republic of China (PRC). Its clinical characteristics are very similar to those of viral pneumonia. After analysis on respiratory samples, PRC Centers for Disease Control (CDC) experts declared that the pneumonia, later known as novel coronavirus pneumonia (NCP), was caused by novel coronavirus.
To date, there is no approved targeted treatment, and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of COVID-19. The availability of a safe and effective vaccine for COVID-19 is well-recognized as an additional tool to contribute to the control of the pandemic. At the same time, the challenges and efforts needed to rapidly develop, evaluate and produce this at scale are enormous. It is vital that as many vaccines as possible are evaluated as it cannot be predicted how many will turn out to be viable.
To increase the chances of success (given the high level of attrition during vaccine development), all candidate vaccines must be tested until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development.
Key Findings
• Around the globe, approx. 150 vaccine candidates (Both academics & industries) are currently under development, in which most of the vaccines are in pre-clinical stage. However, there are approx. 35 clinical vaccine based products of industries under clinical trials currently.
• The players have adopted multiple approaches for the development of vaccines. Some of the approaches adopted by the companies include, whole virus vaccines, subunit vaccines, and nucleic acid based vaccines.
• A significant number of interventional clinical trials are being conducted in China. In addition, a number of trials have recently been initiated in the US and several European countries.
• There are multiple leading research institutes that have received NIH grants for research on coronavirus. Some of the leading academic institutes include, University of North Carolina, University of Iowa, University of Pennsylvania, University of Texas and University of Colorado.
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Emerging Vaccines Chapters
This segment of the COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines report encloses its detailed analysis of various vaccines in different stages of clinical development, including phase III, I/II, and I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included vaccine, and the latest news and press releases.
COVID-19 (Novel Coronavirus 19) Therapeutic Emerging Vaccines
• INO-4800: Inovio Pharmaceuticals
Inovio Pharmaceuticals has begun human clinical trials on their coronavirus vaccine INO-4800 in April 2020. Results from the clinical trials are expected to be available in September 2020. Inovio aims to produce one million doses of the vaccine by the end of 2020 to perform additional clinical trials and/or emergency use of the vaccine. In 10 weeks from funding, INOVIO has manufactured thousands of doses of INO-4800 to support on-going Phase 1 and planned Phase II clinical trials. In parallel, INOVIO is working to scale up the manufacturing of INO-4800. INOVIO plans to have one million doses of the vaccine available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding.
• Ad5-nCoV: CanSino Biologics Inc.
CanSino Biologics Inc. is developing Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate Ad5-nCoV in phase II stage of development for the treatment of COVID-19. It is co-developed with Beijing Institute of Biotechnology (BIB). It is currently the first novel coronavirus vaccine for COVID-19 that made to this stage in China. The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform, which has also been successfully applied to develop the globally innovative vaccine against Ebola virus infection. Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate can induce strong immune response in animal models. The preclinical animal safety studies demonstrated a good safety profile.
• mRNA-1273 Vaccine: Moderna Inc.
mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase II clinical trial. This investigational vaccine was developed using messenger RNA (mRNA) and should direct the body’s cells to express a virus protein that hopefully will elicit a robust immune response, having shown promise in animal models.
• VTP-500: Vaccitech
Vaccitech’s VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein in order to induce T cells, but also antibodies which block virus-host cell receptor binding and fusion or neutralize virus infection. This program has been partnered with University Of Oxford, Janssen and CEPI. The vaccine has now been manufactured according to GMP practice and has been successfully tested in a Phase 1 clinical trial at Oxford University. CEPI, Oxford University and Janssen have entered into a collaboration worth up to $19M to progress the vaccine through Phase 2 studies and establish a human vaccine stockpile. Vaccitech retains commercial rights for the product while licensing certain rights back to Oxford for non-profit development of the vaccine.
• V-SARS: Immunitor
Immunitor is developing therapeutic vaccine V-SARS which is formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunteers for at least one month. It is currently in phase I/II stage of development.
In May 2020, Immunitor initiated phase I/II trial titled “clinical trial of COVID-19 therapeutic vaccine formulated as an oral pill”. The goal of this trial is test safety and immunogenicity of once-per-day day administered orally to volunteers for 15 days. Baseline and post-treatment standard safety parameters will be compared. Blood samples from volunteers will be monitored and immunogenicity lab assays will be undertaken to characterize immune response. The trial is currently in active, not recruiting stage with estimated enrollment of 20 participants and expected to be completed in June 2021.
• SARS-CoV-2 rS Nanoparticle Vaccine: Novavax
Novavax is developing SARS-CoV-2 rS nanoparticle vaccine for the treatment of patients with COVID-19 infections. 2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial designed to evaluate the immunogenicity and safety of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in healthy participants ? 18 to 59 (inclusive) years of age. The study will be conducted in 2 parts. In Part 1, at least 1 and up to two SARS-CoV-2 rS constructs will be evaluated in up to 2 cohorts, which may be enrolled in parallel.
An interim analysis of Part 1 safety and immunogenicity data will be performed prior to an optional expansion to Part 2. This trial is expected to be completed by July 2021.
Further product details are provided in the report…
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Therapeutic Assessment
This segment of the report provides insights about the different Covid-19 emerging vaccines segregated based on following parameters that define the scope of the report, such as:
• Major Key Players
• Phases
• Route of Administration
• Type of Vaccines
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, and Phase I/II stage. It also analyses COVID-19 (Novel Coronavirus 19) therapeutic vaccines key players involved in developing key vaccines.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 (Novel Coronavirus 19) therapeutic Vaccines.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in COVID-19 (Novel Coronavirus 19) therapeutic vaccines domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Scope of the Report
• The report covers the descriptive overview of COVID-19 (Novel Coronavirus 19) therapeutic Vaccines.
• Comprehensive insight has been provided into the COVID-19 (Novel Coronavirus 19) therapeutic Vaccines across the globe.
• Additionally, an all-inclusive account of emerging vaccines for COVID-19 (Novel Coronavirus 19) therapeutic vaccines is provided, along with the assessment of new therapies.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global COVID-19 (Novel Coronavirus 19) therapeutic vaccines market.
Report Highlights
• In the coming years, COVID-19 (Novel Coronavirus 19) therapeutic vaccines market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the vaccine manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 (Novel Coronavirus 19) therapeutic vaccines R&D. The therapies under development are focused on novel approaches to treat/improve Covid-19 infection.
• A better understanding of disease pathogenesis will also contribute to the development of COVID-19 (Novel Coronavirus 19) therapeutic vaccines.
• Our in-depth analysis of the pipeline assets across different stages of development, different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Report Insights
• COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of upcoming Vaccines
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Report Key Strengths
• Global Coverage
• COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Segmentation based on Various Vaccine Types
• Detailed therapeutic Assessment
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Therapeutic Assessment
• SWOT Analysis
• Attribute Analysis
Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing COVID-19 (Novel Coronavirus 19) therapeutic vaccines?
• How many COVID-19 (Novel Coronavirus 19) therapeutic vaccines are developed by each company?
• How many emerging vaccines are in mid-stage, and late-stage of development for the treatment of COVID-19 (Novel Coronavirus 19)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the COVID-19 (Novel Coronavirus 19) therapeutic vaccines?
• What are the recent trends, vaccine types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for COVID-19 (Novel Coronavirus 19) therapeutic vaccines and their status?
• What are the key designations that have been granted to the emerging vaccines?
Reasons to buy
• To understand the future market competition in the COVID-19 (Novel Coronavirus 19) therapeutic vaccines market.
• To understand the Unmet needs in the COVID-19 (Novel Coronavirus 19) therapeutic vaccines.
• To understand the landscape of key emerging vaccines under development for the treatment of COVID-19 (Novel Coronavirus 19).
Read the full report: https://www.reportlinker.com/p05932729/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001